{
    "nctId": "NCT00245050",
    "briefTitle": "Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer",
    "officialTitle": "A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 34,
    "primaryOutcomeMeasure": "Number of Participants With Palmar-plantar Erythrodysesthesia (PPE)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of 1 of the following:\n\n  * Recurrent ovarian, fallopian tube, or peritoneal cavity cancer\n  * Metastatic breast cancer\n  * Advanced endometrial cancer\n* Planning to receive chemotherapy with doxorubicin HCl liposome at a dose of 40 mg/m\\^2\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nSex\n\n* Not specified\n\nMenopausal status:\n\n* Not specified\n\nPerformance status\n\n* Karnofsky 60-100%\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 9.0 g/dL\n\nHepatic\n\n* AST and ALT \u2264 2 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 2 times ULN\n* Bilirubin normal\n\nRenal\n\n* Creatinine \u2264 2.0 mg/dL\n\nCardiovascular\n\n* Ejection fraction \u2265 50% by MUGA or 2-D echocardiogram\n* No history of cardiac disease\n* No New York Heart Association class II-IV heart disease\n* No clinical evidence of congestive heart failure\n\nOther\n\n* Not pregnant or nursing\n* Fertile patients must use effective contraception during and for 3 months after completion of study treatment\n* No active infection requiring antibiotics\n* No history of hypersensitivity reaction attributed to a conventional formulation of doxorubicin HCl or doxorubicin HCl liposome and any of its components\n* No other invasive malignancy within the past 5 years except nonmelanoma or basal cell skin cancer\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* At least 3 weeks since prior biologic or immunologic agents for this cancer\n\nChemotherapy\n\n* Recovered from prior chemotherapy\n\n  * Alopecia or neuropathy allowed\n* No prior doxorubicin HCl liposome\n* Other concurrent chemotherapy allowed provided palmar-plantar erythrodysesthesia is not one of the side effects of the therapy\n\n  * No concurrent cytarabine, fluorouracil, liposomal daunorubicin, or capecitabine\n  * No concurrent pre-medication with corticosteroids as part of the chemotherapy regimen\n\nEndocrine therapy\n\n* See Chemotherapy\n* At least 3 weeks since prior and no concurrent oral or topical corticosteroids\n* At least 1 week since prior hormonal therapy for this cancer\n\n  * Concurrent hormone replacement therapy allowed\n\nRadiotherapy\n\n* At least 3 weeks since prior radiotherapy for this cancer and recovered\n\nSurgery\n\n* Recovered from prior surgery\n\nOther\n\n* At least 3 weeks since prior and no other concurrent forms of pyridoxine except what is included in a multivitamin\n* No prior anticancer treatment that contraindicates study treatment\n* No concurrent amifostine or other protective agents",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}